<li>aceclofenac<p>enoxaparin and aceclofenac both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>acemetacin<p>enoxaparin and acemetacin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>agrimony<p>enoxaparin and agrimony both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>alfalfa<p>enoxaparin and alfalfa both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>alteplase<p>enoxaparin and alteplase both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>american ginseng<p>enoxaparin and american ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>anamu<p>enoxaparin and anamu both increase  anticoagulation. Use Caution/Monitor.</p></li><li>aspirin<p>enoxaparin and aspirin both increase  anticoagulation. Use Caution/Monitor. Additive effects are intended when both drugs are prescribed as indicated for unstable angina, non-Q-wave MI, and STEMI<span><br><br></span>aspirin, enoxaparin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>aspirin rectal<p>enoxaparin and aspirin rectal both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate, enoxaparin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.<span><br><br></span>enoxaparin and aspirin/citric acid/sodium bicarbonate both increase  anticoagulation. Use Caution/Monitor. Additive effects are intended when both drugs are prescribed as indicated for unstable angina, non-Q-wave MI, and STEMI</p></li><li>azapropazone<p>azapropazone increases effects of enoxaparin by plasma protein binding competition. Use Caution/Monitor.</p></li><li>azathioprine<p>azathioprine decreases effects of enoxaparin by unknown mechanism. Use Caution/Monitor.</p></li><li>azficel-t<p>azficel-t, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration with anticoagulants or antiplatelets may increase bruising or bleeding at biopsy and/or injection sites; concomitant use not recommended. Decisions regarding continued use or cessation of anticoagulants or antiplatelets should be made by a physician.</p></li><li>azilsartan<p>enoxaparin increases toxicity of azilsartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>benazepril<p>enoxaparin increases toxicity of benazepril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>budesonide<p>budesonide, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>candesartan<p>enoxaparin increases toxicity of candesartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>captopril<p>enoxaparin increases toxicity of captopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>carbamazepine<p>carbamazepine decreases levels of enoxaparin by increasing metabolism. Use Caution/Monitor.</p></li><li>celecoxib<p>enoxaparin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>chitosan<p>chitosan increases effects of enoxaparin by Other (see comment). Use Caution/Monitor. 
Comment: Chitosan can decrease GI absorption of vitamin K, enhancing anticoagulant effects.</p></li><li>choline magnesium trisalicylate<p>enoxaparin and choline magnesium trisalicylate both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>cinnamon<p>enoxaparin and cinnamon both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>citalopram<p>citalopram increases effects of enoxaparin by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>clobetasone<p>clobetasone, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>clopidogrel<p>enoxaparin, clopidogrel.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Enhanced risk of hemorrhage; additive effects are intended when both drugs are prescribed as indicated for ACS.</p></li><li>collagenase clostridium histolyticum<p>enoxaparin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day).</p></li><li>conjugated estrogens, vaginal<p>conjugated estrogens, vaginal decreases effects of enoxaparin by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Risk of thromboembolic disorders.</p></li><li>cordyceps<p>enoxaparin and cordyceps both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>cornsilk<p>cornsilk decreases effects of enoxaparin by pharmacodynamic antagonism. Use Caution/Monitor. Cornsilk contains vitamin K; consume a consistent amount daily.</p></li><li>cortisone<p>cortisone, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>cyclophosphamide<p>cyclophosphamide increases effects of enoxaparin by unknown mechanism. Use Caution/Monitor. Due to potential thrombocytopenic effects of cyclophosphamide, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants.</p></li><li>danshen<p>enoxaparin and danshen both increase  anticoagulation. Use Caution/Monitor.</p></li><li>deferasirox<p>deferasirox, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Gastric ulceration and GI bleeding have been reported in patients taking deferasirox, use caution when coadministering with other drugs known to increase the risk of peptic ulcers or gastric hemorrhage including anticoagulants.</p></li><li>deflazacort<p>deflazacort, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>devil's claw<p>enoxaparin and devil's claw both increase  anticoagulation. Use Caution/Monitor.</p></li><li>dexamethasone<p>dexamethasone, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>diclofenac<p>enoxaparin and diclofenac both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>diflunisal<p>enoxaparin and diflunisal both increase  anticoagulation. Modify Therapy/Monitor Closely.<span><br><br></span>diflunisal increases effects of enoxaparin by plasma protein binding competition. Use Caution/Monitor.</p></li><li>dong quai<p>enoxaparin and dong quai both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>enalapril<p>enoxaparin increases toxicity of enalapril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>epoprostenol<p>enoxaparin and epoprostenol both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>eprosartan<p>enoxaparin increases toxicity of eprosartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>ethanol<p>ethanol increases effects of enoxaparin by unknown mechanism. Use Caution/Monitor. Acute EtOH intoxication.</p></li><li>ethotoin<p>enoxaparin increases levels of ethotoin by unknown mechanism. Use Caution/Monitor.<span><br><br></span>ethotoin, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Hydantoin anticonvulsants increase anticoagulant effects at first, then decrease those effects with continued use (2+ wks).  There are multiple mechanisms involved, including enzyme induction, plasma protein binding site competition, and additive effects on prothrombin time.</p></li><li>etodolac<p>enoxaparin and etodolac both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>etoricoxib<p>enoxaparin and etoricoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>fenbufen<p>enoxaparin and fenbufen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>fennel<p>enoxaparin and fennel both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>fenoprofen<p>enoxaparin and fenoprofen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>feverfew<p>enoxaparin and feverfew both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>fish oil<p>fish oil, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Patients taking fish oil and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .</p></li><li>fludrocortisone<p>fludrocortisone, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>fluorouracil<p>fluorouracil increases effects of enoxaparin by unspecified interaction mechanism. Use Caution/Monitor. Due to the thrombocytopenic effects of fluorouracil, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants.</p></li><li>flurbiprofen<p>enoxaparin and flurbiprofen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>forskolin<p>enoxaparin and forskolin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>fosinopril<p>enoxaparin increases toxicity of fosinopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>fosphenytoin<p>enoxaparin increases levels of fosphenytoin by unknown mechanism. Use Caution/Monitor.<span><br><br></span>fosphenytoin, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Hydantoin anticonvulsants increase anticoagulant effects at first, then decrease those effects with continued use (2+ wks).  There are multiple mechanisms involved, including enzyme induction, plasma protein binding site competition, and additive effects on prothrombin time.</p></li><li>garlic<p>enoxaparin and garlic both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>gemcitabine<p>gemcitabine increases effects of enoxaparin by unspecified interaction mechanism. Use Caution/Monitor. Due to the thrombocytopenic effects of gemcitabine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants.</p></li><li>ginger<p>enoxaparin and ginger both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>ginkgo biloba<p>enoxaparin and ginkgo biloba both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>glucagon<p>glucagon increases effects of enoxaparin by unknown mechanism. Use Caution/Monitor.</p></li><li>green tea<p>green tea, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase risk of bleeding, caution is advised.</p></li><li>hemin<p>enoxaparin, hemin.
Either increases effects of the other by anticoagulation. Use Caution/Monitor. Hemin degradation product (ie, hematin) may produce coagulopathy (eg, thrombocytopenia, platelet degranulation) and cause mild anticoagulant effects.</p></li><li>horse chestnut seed<p>enoxaparin and horse chestnut seed both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>hydrocortisone<p>hydrocortisone, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>ibuprofen<p>enoxaparin and ibuprofen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>icosapent<p>icosapent, enoxaparin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding.</p></li><li>imatinib<p>imatinib, enoxaparin.
Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents; patients requiring anticoagulation while on imatinib should receive LMWH or unfractionated heparin instead of warfarin because of multiple interaction mechanisms of imatinib with warfarin.</p></li><li>indomethacin<p>enoxaparin and indomethacin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>iodine (radioactive)<p>iodine (radioactive) decreases effects of enoxaparin by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>irbesartan<p>enoxaparin increases toxicity of irbesartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>ketoprofen<p>enoxaparin and ketoprofen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>ketorolac<p>enoxaparin and ketorolac both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>ketorolac intranasal<p>enoxaparin and ketorolac intranasal both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>lisinopril<p>enoxaparin increases toxicity of lisinopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>lofepramine<p>lofepramine increases levels of enoxaparin by decreasing metabolism. Use Caution/Monitor.</p></li><li>lornoxicam<p>enoxaparin and lornoxicam both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>losartan<p>enoxaparin increases toxicity of losartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>meclofenamate<p>enoxaparin and meclofenamate both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>mefenamic acid<p>enoxaparin and mefenamic acid both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>melatonin<p>melatonin increases effects of enoxaparin by anticoagulation. Use Caution/Monitor. Melatonin may decrease prothrombin time.</p></li><li>meloxicam<p>enoxaparin and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>methimazole<p>methimazole decreases effects of enoxaparin by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>methylphenidate<p>methylphenidate increases effects of enoxaparin by decreasing metabolism. Use Caution/Monitor.</p></li><li>methylprednisolone<p>methylprednisolone, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>mistletoe<p>enoxaparin increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>moexipril<p>enoxaparin increases toxicity of moexipril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>nabumetone<p>enoxaparin and nabumetone both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>naproxen<p>enoxaparin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>nettle<p>enoxaparin increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>nintedanib<p>nintedanib increases effects of enoxaparin by anticoagulation. Use Caution/Monitor. Nintedanib is a VEGFR inhibitor, and may increase the risk of bleeding; monitor patients on full anticoagulation therapy; monitor closely for bleeding and adjust therapy as needed .</p></li><li>olmesartan<p>enoxaparin increases toxicity of olmesartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>omega 3 carboxylic acids<p>omega 3 carboxylic acids, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Patients taking omega-3 acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding.</p></li><li>omega 3 fatty acids<p>omega 3 fatty acids, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .</p></li><li>oxaprozin<p>enoxaparin and oxaprozin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>panax ginseng<p>enoxaparin and panax ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>parecoxib<p>enoxaparin and parecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>pau d'arco<p>enoxaparin and pau d'arco both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>pegaspargase<p>pegaspargase increases effects of enoxaparin by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of bleeding events.</p></li><li>perindopril<p>enoxaparin increases toxicity of perindopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>phenytoin<p>enoxaparin increases levels of phenytoin by unknown mechanism. Use Caution/Monitor.<span><br><br></span>phenytoin, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Hydantoin anticonvulsants increase anticoagulant effects at first, then decrease those effects with continued use (2+ wks).  There are multiple mechanisms involved, including enzyme induction, plasma protein binding site competition, and additive effects on prothrombin time.</p></li><li>phytoestrogens<p>enoxaparin and phytoestrogens both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>piroxicam<p>enoxaparin and piroxicam both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>porfimer<p>enoxaparin decreases effects of porfimer by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>prednisolone<p>prednisolone, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>prednisone<p>prednisone, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>propafenone<p>propafenone increases effects of enoxaparin by decreasing metabolism. Use Caution/Monitor.</p></li><li>propylthiouracil<p>propylthiouracil decreases effects of enoxaparin by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>quinapril<p>enoxaparin increases toxicity of quinapril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>ramipril<p>enoxaparin increases toxicity of ramipril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>reishi<p>enoxaparin and reishi both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>reteplase<p>enoxaparin and reteplase both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>rifabutin<p>rifabutin decreases levels of enoxaparin by increasing metabolism. Use Caution/Monitor.</p></li><li>rivaroxaban<p>rivaroxaban, enoxaparin.
Either increases effects of the other by anticoagulation. Use Caution/Monitor. Avoid concurrent use of rivaroxaban with other anticoagulants due to increased bleeding risk other than during therapeutic transition periods where patients should be observed closely. Monitor for signs/symptoms of blood loss.</p></li><li>sacubitril/valsartan<p>enoxaparin increases toxicity of sacubitril/valsartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>salicylates (non-asa)<p>enoxaparin and salicylates (non-asa) both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>salsalate<p>enoxaparin and salsalate both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>saw palmetto<p>saw palmetto increases toxicity of enoxaparin by unspecified interaction mechanism. Use Caution/Monitor. May increase risk of bleeding.</p></li><li>siberian ginseng<p>enoxaparin and siberian ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>sulfasalazine<p>enoxaparin and sulfasalazine both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>sulindac<p>enoxaparin and sulindac both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>telmisartan<p>enoxaparin increases toxicity of telmisartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>tenecteplase<p>enoxaparin and tenecteplase both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>ticagrelor<p>ticagrelor, enoxaparin.
Either increases effects of the other by anticoagulation. Use Caution/Monitor. Increased risk of bleeding during concomitant use of medications that increase potential for bleeding.</p></li><li>tipranavir<p>tipranavir increases effects of enoxaparin by pharmacodynamic synergism. Use Caution/Monitor. Tipranavir has mild antiplatelet activity that may incr bleeding risk.</p></li><li>tolfenamic acid<p>enoxaparin and tolfenamic acid both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>tolmetin<p>enoxaparin and tolmetin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>trandolapril<p>enoxaparin increases toxicity of trandolapril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>triamcinolone<p>triamcinolone, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>triclofos<p>triclofos increases effects of enoxaparin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>valsartan<p>enoxaparin increases toxicity of valsartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>vorapaxar<p>enoxaparin, vorapaxar.
Either increases effects of the other by anticoagulation. Use Caution/Monitor. Coadministration of anticoagulants, antiplatelets, or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding.</p></li><li>vortioxetine<p>enoxaparin, vortioxetine.
Either increases effects of the other by serotonin levels. Use Caution/Monitor.</p></li>